253 related articles for article (PubMed ID: 28922402)
21. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
22. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L
Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420
[TBL] [Abstract][Full Text] [Related]
23. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
[TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of breast cancer subtypes in elderly patients.
Bergen ES; Tichy C; Berghoff AS; Rudas M; Dubsky P; Bago-Horvath Z; Mader RM; Exner R; Gnant M; Zielinski CC; Steger GG; Preusser M; Bartsch R
Breast Cancer Res Treat; 2016 May; 157(1):91-9. PubMed ID: 27107570
[TBL] [Abstract][Full Text] [Related]
25. [Clinical characteristics and prognosis of different subtypes of breast cancer].
Yuan ZY; Wang SS; Zhu MQ; Zheng L; Luo WB; Zhou ZM; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):456-61. PubMed ID: 19024523
[TBL] [Abstract][Full Text] [Related]
26. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological differences between breast cancer in patients with primary metastatic disease and those without: a multicentre study.
Barinoff J; Hils R; Bender A; Groß J; Kurz C; Tauchert S; Mann E; Schwidde I; Ipsen B; Sawitzki K; Heitz F; Harter P; Traut A; du Bois A
Eur J Cancer; 2013 Jan; 49(2):305-11. PubMed ID: 22940292
[TBL] [Abstract][Full Text] [Related]
28. Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990-2011.
Malmgren J; Hurlbert M; Atwood M; Kaplan HG
Breast Cancer Res Treat; 2019 Apr; 174(2):505-514. PubMed ID: 30560462
[TBL] [Abstract][Full Text] [Related]
29. Risk factors for brain relapse in HER2-positive metastatic breast cancer patients.
Duchnowska R; Dziadziuszko R; Czartoryska-Arłukowicz B; Radecka B; Szostakiewicz B; Sosińska-Mielcarek K; Karpińska A; Starosławska E; Kubiatowski T; Szczylik C
Breast Cancer Res Treat; 2009 Sep; 117(2):297-303. PubMed ID: 19130219
[TBL] [Abstract][Full Text] [Related]
30. Outcome in breast molecular subtypes according to nodal status and surgical procedures.
Mazouni C; Rimareix F; Mathieu MC; Uzan C; Bourgier C; André F; Delaloge S; Garbay JR
Am J Surg; 2013 Jun; 205(6):662-7. PubMed ID: 23312273
[TBL] [Abstract][Full Text] [Related]
31. Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. a single institution survey spanning 1998 to 2010.
García Fernández A; Giménez N; Fraile M; González S; Chabrera C; Torras M; González C; Salas A; Barco I; Cirera L; Cambra MJ; Veloso E; Pessarrodona A
Breast; 2012 Jun; 21(3):366-73. PubMed ID: 22487206
[TBL] [Abstract][Full Text] [Related]
32. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
[TBL] [Abstract][Full Text] [Related]
33. Long-term prognoses and outcomes of axillary lymph node recurrence in 2,578 sentinel lymph node-negative patients for whom axillary lymph node dissection was omitted: results from one Japanese hospital.
Ogiya A; Kimura K; Nakashima E; Sakai T; Miyagi Y; Iijima K; Morizono H; Makita M; Horii R; Akiyama F; Iwase T
Breast Cancer; 2016 Mar; 23(2):318-22. PubMed ID: 25376341
[TBL] [Abstract][Full Text] [Related]
34. Pattern of metastasis and outcome in patients with breast cancer.
Gerratana L; Fanotto V; Bonotto M; Bolzonello S; Minisini AM; Fasola G; Puglisi F
Clin Exp Metastasis; 2015 Feb; 32(2):125-33. PubMed ID: 25630269
[TBL] [Abstract][Full Text] [Related]
35. Effect of HER2 status on distant recurrence in early stage breast cancer.
Hess KR; Esteva FJ
Breast Cancer Res Treat; 2013 Jan; 137(2):449-55. PubMed ID: 23225147
[TBL] [Abstract][Full Text] [Related]
36. Distant metastasis in triple-negative breast cancer.
Tseng LM; Hsu NC; Chen SC; Lu YS; Lin CH; Chang DY; Li H; Lin YC; Chang HK; Chao TC; Ouyang F; Hou MF
Neoplasma; 2013; 60(3):290-4. PubMed ID: 23373998
[TBL] [Abstract][Full Text] [Related]
37. Importance of confirming HER2 overexpression of recurrence lesion in breast cancer patients.
Nakamura R; Yamamoto N; Onai Y; Watanabe Y; Kawana H; Miyazaki M
Breast Cancer; 2013 Oct; 20(4):336-41. PubMed ID: 22367960
[TBL] [Abstract][Full Text] [Related]
38. Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer.
Dieci MV; Conte P; Bisagni G; Bartolini S; Frassoldati A; Generali D; Piacentini F; Griguolo G; Tagliafico E; Brasó Maristany F; Chic N; Paré L; Miglietta F; Vicini R; D'Amico R; Balduzzi S; Prat A; Guarneri V
J Natl Cancer Inst; 2024 Jan; 116(1):69-80. PubMed ID: 37676829
[TBL] [Abstract][Full Text] [Related]
39. Staging of women with breast cancer after introduction of sentinel node guided axillary dissection.
Tvedskov TF
Dan Med J; 2012 Jul; 59(7):B4475. PubMed ID: 22759850
[TBL] [Abstract][Full Text] [Related]
40. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
